CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib

Overview of attention for article published in BioDrugs, March 2019

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 75 Dimensions

Readers on

mendeley: 125 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 297 followers.

CDK4/6 Inhibitors Expand the Therapeutic Options in #BreastCancer: Palbociclib, Ribociclib and Abemaciclib https://t.co/C1qTrjhvxc https://t.co/onhSdV5M9R

Reply Repost Favourite